Danaher Co. (NYSE:DHR) Declares $0.27 Quarterly Dividend

Danaher Co. (NYSE:DHR) announced a quarterly dividend on Tuesday, December 10th,RTT News reports. Investors of record on Friday, December 27th will be paid a dividend of 0.27 per share by the conglomerate on Friday, January 31st. This represents a $1.08 annualized dividend and a yield of 0.46%.

Danaher has increased its dividend by an average of 13.4% per year over the last three years. Danaher has a payout ratio of 12.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Danaher to earn $8.38 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 12.9%.

Danaher Price Performance

NYSE:DHR traded up $2.99 during midday trading on Wednesday, hitting $237.33. 211,544 shares of the stock were exchanged, compared to its average volume of 2,767,756. Danaher has a one year low of $218.48 and a one year high of $281.70. The company has a market capitalization of $171.42 billion, a price-to-earnings ratio of 44.74, a P/E/G ratio of 4.23 and a beta of 0.83. The business has a 50-day moving average price of $249.91 and a two-hundred day moving average price of $258.14. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 earnings per share. Sell-side analysts predict that Danaher will post 7.5 EPS for the current year.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research analyst reports. Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Wells Fargo & Company initiated coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Finally, TD Cowen boosted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.